NEW YORK (GenomeWeb) – Response Genetics reported today a roughly 3 percent drop in its first quarter revenues as an increase in test order volume was offset by lower reimbursement.

The Los Angeles-based molecular diagnostic testing services firm reported total revenues of $3.8 million for the three months ended March 31, down from $3.9 million in Q1 2014. It said that sales associated with its ResponseDx tests were $3.3 million, consistent with the first quarter of 2014. However, its pharmaceutical client revenue slipped to $500,000 from $600,000 year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.